Asarina Pharma

Resolution on voluntary liquidation
The general meeting resolved in accordance with the board of directors' proposal that the company shall enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Swedish Companies Act. The resolution on liquidation is proposed to take effect as of 1 December 2024. The reason for this is that payments are expected to be received by the company's Danish subsidiary Asarina Pharma ApS during November. The distribution of any liquidation proceeds is expected to take place in connection with the expiry of the time for calling unknown creditors, or at the latest in connection with the presentation of the liquidator’s final report. No probate proceeds are prudently anticipated. The board of directors had not presented a proposal for a liquidator to the general meeting.